Integrative oncology for young adults with cancer: A prospective pragmatic controlled trial [0.03%]
癌症综合肿瘤学的整合医学治疗：一项务实型前瞻性的控制试验
Eran Ben-Arye,Shahar Samuel,Ilit Turgeman et al.
Eran Ben-Arye et al.
Research on the impact of integrative oncology (IO) programs on quality of life (QoL) among young adults with cancer is limited. The present study explored the impact of a patient-tailored IO program for young patients undergoing active onc...
Harnessing nanoparticles to unlock the therapeutic potential of triptolide in cancer treatment [0.03%]
纳米颗粒在癌症治疗中的应用：激活三氧茋类化合物的抗癌潜力
Sambhavi Swarn,Tanvi Desai,Sonam M Gandhi et al.
Sambhavi Swarn et al.
Cancer is the second leading cause of death globally, responsible for nearly 9.8 million deaths and 19.2 million new cases annually, a figure projected to rise to 13 million deaths and over 21 million new cases by 2030. Despite advances in ...
Lactate and lactylation in hepatocellular carcinoma: A new frontier in metabolic-epigenetic interactions [0.03%]
肝细胞癌中的乳酸和乳酸化：代谢-表观遗传相互作用的新前沿
Chen Chen,Yangyang Miao,Songsong Fan et al.
Chen Chen et al.
Hepatocellular carcinoma (HCC) is a highly prevalent malignancy with persistently high and increasing mortality rates. Once regarded merely as a metabolic byproduct, lactate is now recognized as a key metabolite in the tumor microenvironmen...
Correction to: LncRNA LOXL1-AS1 promotes ovarian cancer progression by enhanced BRIP1 mRNA stability [0.03%]
长非编码RNA LOXL1-AS1通过增强BRIP1 mRNA稳定性促进卵巢癌进展的校正文章
Su Wan,Chang Su,Jin Ding et al.
Su Wan et al.
The overlooked role of genetic ancestry in global breast cancer burden estimates [0.03%]
被忽视的遗传祖先在全球乳腺癌负担估算中的作用
Howard Lopes Ribeiro Jr,Cláudia do Ó Pessoa,Pâmela Borges et al.
Howard Lopes Ribeiro Jr et al.
Repurposing statins for the management of head and neck squamous cell carcinoma: A systematic review of preclinical and clinical evidence [0.03%]
他汀类药物在头颈部鳞状细胞癌治疗中的再利用：对临床前和临床证据的系统回顾
Paras Famta,Ganesh Vambhurkar,Giriraj Pandey et al.
Paras Famta et al.
Statins are marketed as antihyperlipidemic drugs, have been repurposed in cancer management. Their repurposing is based on antiproliferative, apoptotic, and anti-metastatic properties. Head and neck cancer, including oral carcinoma, remains...
Metabolic vulnerabilities in advanced prostate cancer: the interplay of ferroptosis, cuproptosis, and the inflammatory microenvironment [0.03%]
前列腺癌代谢脆弱性：铁死亡、铜死亡和炎症微环境的相互作用
Farzaneh Motafeghi,Parham Mortazavi,Mohammad Hossein Hosseinzadeh et al.
Farzaneh Motafeghi et al.
Advanced prostate cancer, particularly metastatic castration-resistant disease (mCRPC), represents a major clinical challenge due to its evasion of classical apoptotic pathways. Exploiting alternative regulated cell death modalities, specif...
P38MAPK targeting in pancreatic ductal adenocarcinoma: Promising interventional approach for breaking drug resistance and tumor control [0.03%]
胰腺导管腺癌的P38MAPK靶向治疗：克服药物耐药性和控制肿瘤的前景干预措施
Vandana Mehra,Khushi Gandhi,Clara Freixinos et al.
Vandana Mehra et al.
Pancreatic cancer is one of the deadliest cancers and has very limited therapeutic options and a dismal prognosis with less than 11% median survival rate. Among various signaling pathways which are involved during tumor development, hyperac...
Correction to: Antisense LNA GapmeR targeting hsa‑piR‑33195 induces antiproliferative and apoptotic effects on human acute myeloid leukemia [0.03%]
特异性LNA反义寡核苷酸抑制人急性髓系白血病的增殖和诱导凋亡作用及其机制研究纠正：hsa-piR-33195
Musarreza Shiri,Mohammadreza Sharifi,Hassan Dianat-Moghadam et al.
Musarreza Shiri et al.
Correction to: Response evaluations in non-small cell lung cancer patients undergoing immunotherapy: A comparative analysis of RECIST 1.1, iRECIST, and imRECIST criteria [0.03%]
对免疫治疗非小细胞肺癌患者的反应评估：RECIST 1.1、iRECIST 和 imRECIST 标准的比较分析的校正
Yun-Ju Shih,Jeon-Hor Chen,Li-Ren Yeh et al.
Yun-Ju Shih et al.